Carvedilol pharmacokinetics and pharmacodynamics in relation to CYP2D6 and ADRB pharmacogenetics

Pharmacogenomics

Volumn 12, Issue 6, 2011, Pages 783-795

  Sehrt, Daniel ^a   Meineke, Ingolf ^a   Tzvetkov, Mladen ^a   Gültepe, Senol ^a   Brockmöller, Jürgen ^a  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

Author keywords

ADRB1; ADRB2; adrenergic receptor polymorphism; carvedilol; CYP2D6 polymorphism; heart failure; hypertension; PKPD modeling; population pharmacokinetics

Indexed keywords

CARVEDILOL;

ADRB GENE; ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD PRESSURE; CONCENTRATION LOSS; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYP2D6 GENE; DIZZINESS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFECT; DRUG ELIMINATION; EXERCISE; FATIGUE; FEMALE; FIRST PASS EFFECT; GENE; GENETIC ASSOCIATION; GENOTYPE; HEART RATE; HETEROZYGOTE; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PHARMACODYNAMICS; PHARMACOGENETICS; REST; UNSPECIFIED SIDE EFFECT; VOLUNTEER;

ADULT; ALLELES; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CARBAZOLES; CYTOCHROME P-450 CYP2D6; FEMALE; GENOTYPE; HEART FAILURE; HEART RATE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; PHARMACOGENETICS; POLYMORPHISM, GENETIC; PROPANOLAMINES; RECEPTORS, ADRENERGIC, BETA-1; RECEPTORS, ADRENERGIC, BETA-2; YOUNG ADULT;

EID: 79959415785     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.11.20     Document Type: Article

References (38)

1. Bartsch W, Sponer G, Strein K et al.: Pharmacological characteristics of the stereoisomers of carvedilol. Eur. J. Clin. Pharmacol. 38(Suppl. 2), S104-S107 (1990). (Pubitemid 20183992)
2. Oldham HG, Clarke SE: In vitro identification of the human cytochrome P450 enzymes involved in the metabolism of R(+)- and S(-)-carvedilol. Drug Metab. Dispos. 25(8), 970-977 (1997). (Pubitemid 27357695)
3. Zhou HH, Wood AJ: Stereoselective disposition of carvedilol is determined by CYP2D6. Clin. Pharmacol. Ther. 57(5), 518-524 (1995).
4. Honda M, Nozawa T, Igarashi N et al.: Effect of CYP2D6*10 on the pharmacokinetics of R- and S-carvedilol in healthy Japanese volunteers. Biol. Pharm. Bull. 28(8), 1476-1479 (2005). (Pubitemid 41379702)
5. Takekuma Y, Takenaka T, Kiyokawa M et al.: Contribution of polymorphisms in UDP-glucuronosyltransferase and CYP2D6 to the individual variation in disposition of carvedilol. J. Pharm. Pharm. Sci. 9(1), 101-112 (2006). (Pubitemid 43338063)
6. Giessmann T, Modess C, Hecker U et al.: CYP2D6 genotype and induction of intestinal drug transporters by rifampin predict presystemic clearance of carvedilol in healthy subjects. Clin. Pharmacol. Ther. 75(3), 213-222 (2004). (Pubitemid 38314871)
7. Saito M, Kawana J, Ohno T et al.: Population pharmacokinetics of R- and S-carvedilol in Japanese patients with chronic heart failure. Biol. Pharm. Bull. 33(8), 1378-1384 (2010).
8. Graff DW, Williamson KM, Pieper JA et al.: Effect of fluoxetine on carvedilol pharmacokinetics, CYP2D6 activity, and autonomic balance in heart failure patients. J. Clin. Pharmacol. 41(1), 97-106 (2001).
9. Baudhuin LM, Miller WL, Train L et al.: Relation of ADRB1, CYP2D6, and UGT1A1 polymorphisms with dose of, and response to, carvedilol or metoprolol therapy in patients with chronic heart failure. Am. J. Cardiol. 106(3), 402-408 (2010).
10. Dorn GW 2nd, Liggett SB: Mechanisms of pharmacogenomic effects of genetic variation within the cardiac adrenergic network in heart failure. Mol. Pharmacol. 76(3), 466-480 (2009).
11. Liggett SB, Mialet-Perez J, Thaneemit- Chen S et al.: A polymorphism within a conserved b(1)-adrenergic receptor motif alters cardiac function and b-blocker response in human heart failure. Proc. Natl Acad. Sci. USA 103(30), 11288-11293 (2006). (Pubitemid 44156511)
12. Mason DA, Moore JD, Green SA et al.: A gain-of-function polymorphism in a G-protein coupling domain of the human b1-adrenergic receptor. J. Biol. Chem. 274(18), 12670-12674 (1999).
13. Rathz DA, Brown KM, Kramer LA et al.: Amino acid 49 polymorphisms of the human b1-adrenergic receptor affect agonist-promoted trafficking. J. Cardiovasc. Pharmacol. 39(2), 155-160 (2002). (Pubitemid 34093534)
14. Sehnert AJ, Daniels SE, Elashoff M et al.: Lack of association between adrenergic receptor genotypes and survival in heart failure patients treated with carvedilol or metoprolol. J. Am. Coll. Cardiol. 52(8), 644-651 (2008).
15. Small KM, Wagoner LE, Levin AM et al.: Synergistic polymorphisms of b1- and a2C-adrenergic receptors and the risk of congestive heart failure. N. Engl. J. Med. 347(15), 1135-1142 (2002).
16. Rochais F, Vilardaga JP, Nikolaev VO et al.: Real-time optical recording of b1-adrenergic receptor activation reveals supersensitivity of the Arg389 variant to carvedilol. J. Clin. Invest. 117(1), 229-235 (2007). (Pubitemid 46048469)
17. Johnson JA, Zineh I, Puckett BJ et al.: b 1-adrenergic receptor polymorphisms and antihypertensive response to metoprolol. Clin. Pharmacol. Ther. 74(1), 44-52 (2003). (Pubitemid 36776175)
18. Pacanowski MA, Gong Y, Cooper-Dehoff RM et al.: b-adrenergic receptor gene polymorphisms and b-blocker treatment outcomes in hypertension. Clin. Pharmacol. Ther. 84(6), 715-721 (2008).
19. Molenaar P, Christ T, Ravens U et al.: Carvedilol blocks b2- more than b1- adrenoceptors in human heart. Cardiovasc. Res. 69(1), 128-139 (2006).
20. Green SA, Turki J, Innis M et al.: Amino-terminal polymorphisms of the human b2-adrenergic receptor impart distinct agonist-promoted regulatory properties. Biochemistry 33(32), 9414-9419 (1994). (Pubitemid 24272896)
21. Kaye DM, Smirk B, Williams C et al.: b-adrenoceptor genotype influences the response to carvedilol in patients with congestive heart failure. Pharmacogenetics 13(7), 379-382 (2003). (Pubitemid 36900732)
22. Dunn CJ, Lea AP, Wagstaff AJ: Carvedilol. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders. Drugs 54(1), 161-185 (1997). (Pubitemid 27300048)
23. Lovlie R, Daly AK, Matre GE et al.: Polymorphisms in CYP2D6 duplication-negative individuals with the ultrarapid metabolizer phenotype: a role for the CYP2D6*35 allele in ultrarapid metabolism? Pharmacogenetics 11(1), 45-55 (2001). (Pubitemid 32108661)
24. McElroy S, Sachse C, Brockmöller J et al.: CYP2D6 genotyping as an alternative to phenotyping for determination of metabolic status in a clinical trial setting. AAPS PharmSci. 2(4), E33 (2000).
25. Abduljalil K, Frank D, Gaedigk A et al.: Assessment of activity levels for CYP2D6*1, CYP2D6*2, and CYP2D6*41 genes by population pharmacokinetics of dextromethorphan. Clin. Pharmacol. Ther. 88(5), 643-651 (2010).
26. Bapiro TE, Hasler JA, Ridderstrom M et al.: The molecular and enzyme kinetic basis for the diminished activity of the cytochrome P450 2D6.17 (CYP2D6.17) variant. Potential implications for CYP2D6 phenotyping studies and the clinical use of CYP2D6 substrate drugs in some African populations. Biochem. Pharmacol. 64(9), 1387-1398 (2002). (Pubitemid 35248255)
27. Lennard MS, Iyun AO, Jackson PR et al.: Evidence for a dissociation in the control of sparteine, debrisoquine and metoprolol metabolism in Nigerians. Pharmacogenetics 2(2), 89-92 (1992).
28. Steimer W, Zopf K, von Amelunxen S et al.: Allele-specific change of concentration and functional gene dose for the prediction of steady-state serum concentrations of amitriptyline and nortriptyline in CYP2C19 and CYP2D6 extensive and intermediate metabolizers. Clin. Chem. 50(9), 1623-1633 (2004). (Pubitemid 39121231)
29. Kirchheiner J, Heesch C, Bauer S et al.: Impact of the ultrarapid metabolizer genotype of cytochrome P450 2D6 on metoprolol pharmacokinetics and pharmacodynamics. Clin. Pharmacol. Ther. 76(4), 302-312 (2004). (Pubitemid 39313120)
30. Kirchheiner J, Fuhr U, Brockmöller J: Pharmacogenetics-based therapeutic recommendations - ready for clinical practice? Nat. Rev. Drug Discov. 4(8), 639-647 (2005). (Pubitemid 41149757)
31. Gaedigk A, Simon SD, Pearce RE et al.: The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. Clin. Pharmacol. Ther. 83(2), 234-242 (2008).
32. Honda M, Ogura Y, Toyoda W et al.: Multiple regression analysis of pharmacogenetic variability of carvedilol disposition in 54 healthy Japanese volunteers. Biol. Pharm. Bull. 29(4), 772-778 (2006).
33. Ohno A, Saito Y, Hanioka N et al.: Involvement of human hepatic UGT1A1, UGT2B4, and UGT2B7 in the glucuronidation of carvedilol. Drug Metab. Dispos. 32(2), 235-239 (2004). (Pubitemid 38176941)
34. Riley MS, Porszasz J, Engelen MP et al.: Responses to constant work rate bicycle ergometry exercise in primary pulmonary hypertension: the effect of inhaled nitric oxide. J. Am. Coll. Cardiol. 36(2), 547-556 (2000). (Pubitemid 30624020)
35. Wilk JB, Myers RH, Pankow JS et al.: Adrenergic receptor polymorphisms associated with resting heart rate: the HyperGEN Study. Ann. Hum. Genet. 70(Pt 5), 566-573 (2006). (Pubitemid 44173368)
36. Ranade K, Jorgenson E, Sheu WH et al.: A polymorphism in the b1 adrenergic receptor is associated with resting heart rate. Am. J. Hum. Genet. 70(4), 935-942 (2002). (Pubitemid 34259309)
37. Eijgelsheim M, Newton-Cheh C, Sotoodehnia N et al.: Genome-wide association analysis identifies multiple loci related with resting heart rate. Hum. Mol. Genet. 19(19), 3885-3894 (2010).
38. Evans WE, Relling MV: Pharmacogenomics: translating functional genomics into rational therapeutics. Science 286(5439), 487-491 (1999).